Decyd provides an AI‑powered launch intelligence platform for biopharma companies, using 15 years of drug launch data to identify parallel brands with comparable challenges. By delivering a traceable, working document that highlights hidden risk factors and success accelerators, Decyd helps teams make informed decisions on portfolio choice, launch sequencing, and commercial strategy before critical meetings. The service integrates regulatory, therapeutic, and market context to generate actionable insights for upcoming launch decisions.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharma teams rely on internal expertise, limited data subscriptions, and personal networks that often miss relevant analogues from past drug launches, leading to blind spots in portfolio, sequencing, and positioning decisions. Without systematic comparison to prior launches, companies struggle to identify hidden risks and success factors before critical milestones.
Solution
Decyd offers an AI‑powered launch intelligence platform that processes 15 years of drug launch data to surface parallel brands matching a user’s therapeutic, regulatory, and commercial context. Users submit a brief question, and the system returns a traceable working document that cites each analogue and highlights hidden risk factors (“Killers”) and success accelerators. By quantifying both approval probability and commercial viability, Decyd bridges the “readiness gap” between regulatory success and market performance. The output is designed for immediate use in decision meetings, enabling teams to make evidence‑based portfolio, sequencing, and positioning choices without relying on ad‑hoc networks or generic data feeds.
Target Audience
Primary customers are biopharma portfolio managers, launch strategists, and business development teams who need data‑driven insights for drug launch planning and investment decisions.
Features
- AI-driven search of 15 years of public drug launch data to identify directly comparable parallel brands
- Automated generation of a traceable working document linking findings to source analogues
- Classification of analogues into “Hidden Killers” and “Success Accelerators” to surface risk and opportunity patterns
- Dual scoring of approval probability and commercial viability to highlight the readiness gap
- Integration of therapeutic area, target profile, regulatory pathway, competitive context, and commercial model in analogue matching
- Ability to address portfolio selection, launch sequencing, indication choice, positioning, and BD term‑sheet decisions with a single paragraph input